Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
- ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16 after three monthly doses. - ASC30 SQ depot formulation maintained weight loss for the four...
LEIFRAS Co., Ltd. Announces Alliance with Blaublitz Akita to Launch "Blaublitz Akita × Liberta Soccer School"
Marking the Company's First Entry into Akita Prefecture and Its Expansion to 46 Prefectures Nationwide TOKYO, March 10, 2026 /PRNewswire/ -- LEIFRAS Co., Ltd. (Nasdaq: LFS) (the "Company" or "Leifras"), a sports and social business company dedicated...
MaestroWellness Announces Inaugural Build Well Live Well Summit on 26 March 2026, in Hong Kong
Convening cross-sector leaders to align capital, policy and innovation around measurable healthspan outcomes HONG KONG, March 10, 2026 /PRNewswire/ -- MaestroWellness announces the inaugural Build Well Live Well (BWLW) Summit, a cross-sector forum...
Yalla Group Limited Announces New US$150 Million Share Repurchase Program
DUBAI, UAE, March 10, 2026 /PRNewswire/ -- Yalla Group Limited ("Yalla" or the "Company") (NYSE: YALA), the largest Middle East and North Africa (MENA)-based online social networking and gaming company, today announced that its board of directors...
Yalla Group Limited Announces Unaudited Fourth Quarter and Full Year 2025 Financial Results
DUBAI, UAE, March 10, 2026 /PRNewswire/ -- Yalla Group Limited ("Yalla" or the "Company") (NYSE: YALA), the largest Middle East and North Africa (MENA)-based online social networking and gaming company, today announced its unaudited financial...
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY® in Mainland China
SHANGHAI, March 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today...
YY Group Announces Preliminary Fiscal Year 2025 Financial Highlights
Estimated revenue of US$57 million to US$58 million, up 38.7% to 41.1% YOY Estimated gross profit of US$7.5 million to US$8 million, up 42.6% to 52.1% YOY SINGAPORE, March 9, 2026 /PRNewswire/ -- YY Group Holding Limited (NASDAQ: YYGH) ("YY Group"...
Acer Announces February Revenues at NT$21.46 Billion, a Record High for February Post Pandemic, up 25.7% Year-on-year
TAIPEI, March 9, 2026 /PRNewswire/ -- Acer Inc. (TWSE: 2353) announced its consolidated revenues for February at NT$21.46 billion, with growth of 25.7% year-on-year (YoY) and 1.8% month-on-month. Consolidated revenues for year-to-February reached...
Elong Power Holding Limited Announces the Change of Effective Date of its 1 for 80 Share Consolidations
BEIJING, March 7, 2026 /PRNewswire/ -- Elong Power Holding Limited (Nasdaq: ELPW) (the "Company"), a provider of high power battery technologies for commercial and specialty alternative energy vehicles and energy storage systems, announced a share...
CARsgen Therapeutics Announces 2025 Annual Results
SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results. Business Highlights Cash and cash...